Abstract PS1-10-09: Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients with ER+/HER2− metastatic breast cancer: results from phase 1 study to support the recommended phase 3 dose
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Yale University, National Cancer Center Hospital East, National Cancer Center Hospital, Sarah Cannon, The University of Texas MD Anderson Cancer Center, Asan Medical Center, University of Ulsan, Seoul National University, City Of Hope National Medical Center, University of California, San Francisco, City of Hope, Kanagawa Cancer Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Yonsei University, Yonsei University Health System, Sun Yat-sen University, Pfizer (United States), Samsung Medical Center, Sungkyunkwan University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129551847